eligibility_summary
Eligible: CD33/FLT3+ heme malignancy—R/R AML (≥5% marrow blasts, 1–3 prior lines, FLT3/IDH-mutant had targeted therapy), R/R MDS w/ increased blasts (1–2 lines), or other heme cancers (≥1 line), documented antigen, ECOG 0–1, adequate organs/platelets, recovered toxicities. Exclude: WBC ≥20×10^9/L or circ. blasts ≥10×10^9/L or hyperproliferative, APL t(15,17), MDS-f, CNS disease, extramedullary-only, recent disallowed Rx/HCT<100d, prior NK/CAR T, most DLI (except post-HCT MRD+), pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: SENTI-202, an investigational biologic, off-the-shelf allogeneic CAR NK cell therapy for CD33 and/or FLT3-positive hematologic malignancies (AML/MDS and related). Mechanism: logic-gated NOT design combining activating CAR(s) targeting CD33 and/or FLT3 with an inhibitory CAR to spare healthy cells, includes IL-15 support to enhance NK persistence/function. Given after lymphodepleting chemotherapy with fludarabine (purine analog antimetabolite) and cytarabine/Ara-C (pyrimidine analog antimetabolite). Targets: malignant myeloid cells/blasts expressing CD33 and/or FLT3, engaging the FLT3 receptor tyrosine kinase pathway and CD33 surface antigen, while minimizing effects on normal hematopoietic cells.